Clinical trial
Study Evaluating Three Bazedoxifene/Conjugated Estrogens Combination Tablet…
NCT00367536 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00367536 |
|---|---|
| Title | Study Evaluating Three Bazedoxifene/Conjugated Estrogens Combination Tablet Formulations Versus BZA Oral Solution |
| Official title | An Open-label, Single-dose, Randomized-to-sequence, 4-period Crossover Bioavailability Study of Bazedoxifene Contained in Bazedoxifene/Conjugated Estrogen Tablets Administered to Healthy Postmenopausal Women. |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Postmenopause |
| Intervention type | Drug |
| Interventions | bazedoxifene/conjugated estrogens combination tablet |
| Enrollment | 24 |
| Start date | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Aug 23, 2006 |
| Last update posted | May 1, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: